Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause
Recruitment status was Recruiting
Pulmonary Hypertension (PH) is a disease that is characterized by vasoconstriction of small vessels of the lung. Many cases do have proliferation of endothelial cells within these vessels. A possible influence of polymorphisms of genes relevant for inflammatory and endothelial processes is suspected.
Especially patients with chronic heart failure can develope PH. The reasons therefore are lacking.
The researchers investigate different polymorphism and the influence of these on pulmonary artery pressure (measured invasively) in patients with congestive heart failure (CHF) and patients with primary pulmonary hypertension.
Congestive Heart Failure
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Impact of Different Genetic Polymorphism on the Pulmonary Pressure in Patients With Pulmonary Hypertension of Different Cause With Special Focus on Patients With Chronic Heart Failure|
- Correlation of the Expression of Glu 298ASP Polymorphism with pulmonary pressure [ Time Frame: Dec. 2010 ] [ Designated as safety issue: No ]
- Rate of G308A TNF alpha polymorphism within the different groups [ Time Frame: Dec. 2010 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||December 2007|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
CHF with elevated PAP
CHF patients (LVEF > 35%) with elevated mean pulmonary pressure( > 20 mmHg ) measured by pa catheter
CHF patient without elevated PAP
CHF patients (LVEF > 35%) with normal mean pulmonary pressure
Normal EF with elevated PAP
Patients with normal LVEF < 60% with elevated mean pulmonary pressure
The study consists of 3 arms-patients with CHF and PH, patients with CHF without PH and patients without CHF and PH.
The PH measurement is due to routine catheterization, thereafter we measure different vasoactive polymorphism.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00893178
|Heart Center Leipzig- University Leipzig||Recruiting|
|Leipzig, Germany, 04289|
|Contact: Sven Moebius-Winkler, M.D. 0049-341-865 ext 1474 email@example.com|
|Contact: Volker Adams, PhD firstname.lastname@example.org|
|Principal Investigator:||Sven Möbius-Winkler, M.D||University Leipzig-Heart Center|